Literature DB >> 18657140

National adoption of sentinel node biopsy for breast cancer: lessons learned from the Canadian experience.

May Lynn Quan1, Nicole Hodgson, Peter Lovrics, Geoff Porter, Brigitte Poirier, Frances C Wright.   

Abstract

Sentinel lymph node biopsy (SLNB) in breast cancer has not been readily adopted into Canadian surgical practice in comparison with the United States. We sought to evaluate current national practice patterns and explore barriers to direct efforts to improve the adoption of SLNB in Canada. All active (n = 1413) general surgeons in Canada were surveyed by mail. Surgeon demographics, practice patterns, skill acquisition and attitudes towards SLNB were assessed. The response rate was 63% (n = 889). Of the 506 (57%) surgeons who treated breast cancer, half were community based with breast surgery comprising <25% of their practices. Most (70%) performed <or=5 breast surgeries/month. Almost all (96%) believed SLNB was standard of care or an acceptable alternative to axillary lymph node dissection (ALND). Of these, 306 (61%) performed SLNB. Predictors of performing SLNB were breast/oncology fellowship (p = 0.03) or greater percentage of practice dedicated to breast (p = 0.02) but not region, type of practice (community versus academic), gender or year of residency completion. Reasons for performing SLNB were decreased morbidity (85%) and enhanced staging (59%) as opposed to competitive pressure (13%). The majority (75%) performed SLNB as a stand-alone procedure for T1/T2 cancers and high-risk ductal carcinoma in situ (70%). Almost half (46%) abandoned back up ALND after 30 or fewer cases even though the majority (75%) acknowledged the false-negative rate should be <5%. Most (76%) learned SLNB through mentoring or a formal course/residency. Of the 197 (39%) not performing SLNB, 53% felt that inadequate access to nuclear medicine and gamma probe equipment was the predominant barrier. SLNB has been adopted into Canadian surgical practice. The majority of surgeons believe that SLNB is an acceptable alternative to ALND, with 61% now performing SLNB compared to 27% in 2001. Barriers to implementation appear to be related to inadequate resources as opposed to lack of belief in the procedure.

Entities:  

Mesh:

Year:  2008        PMID: 18657140     DOI: 10.1111/j.1524-4741.2008.00617.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  4 in total

1.  Assessing patterns of practice of sentinel lymph node biopsy for breast cancer in Latin America.

Authors:  Sergio A Acuna; Fernando A Angarita; Jaime Escallon
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

2.  Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients.

Authors:  Joost R van der Vorst; Boudewijn E Schaafsma; Floris P R Verbeek; Merlijn Hutteman; J Sven D Mieog; Clemens W G M Lowik; Gerrit-Jan Liefers; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer
Journal:  Ann Surg Oncol       Date:  2012-07-03       Impact factor: 5.344

3.  How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study.

Authors:  Robin Urquhart; Cynthia Kendell; Joan Sargeant; Gordon Buduhan; Paul Johnson; Daniel Rayson; Eva Grunfeld; Geoffrey A Porter
Journal:  Implement Sci       Date:  2012-10-25       Impact factor: 7.327

4.  Trends in the surgical procedures of women with incident breast cancer in Catalonia, Spain, over a 7-year period (2005-2011).

Authors:  Josep M Escribà; Laura Pareja; Laura Esteban; Jordi Gálvez; Angels Melià; Laura Roca; Ramon Clèries; Xavier Sanz; Montse Bustins; María J Pla; Miguel J Gil; Josep M Borrás; Josepa Ribes
Journal:  BMC Res Notes       Date:  2014-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.